loading... download flash
spacer spacer spacer spacer spacer
 
 

Pipeline and Research

CV Therapeutics has the following portfolio of products and product candidates, primarily in the area of cardiovascular disease.

CV Therapeutics Development Pipeline, ranolazine, chronic angina, regadenoson, myocardial perfusion imaging, tecadenoson, paroxysmal supraventricular tachycardia, acute atrial fibrillation, Adentri, heart failure, 6883, asthma, adenosine, adenosine receptors, atrial arrhythmias, lipid metabolism, diabetes, metabolic syndrome, dyslipidemia, addiction, late sodium, late sodium current, ischemic conditions, reverse cholesterol transport, atherosclerosis.

Pipeline last updated November 6, 2008. To view a larger version of this image, click here.

In the table, the bar denoting development status indicates the most advanced stage of development that has been completed or is in process.
Printer Friendly Page
spacer
spacer
spacer spacer
Back to Top
footer header
Home | About CVT | Media | Investors | Careers | Terms of Use | Privacy Policy | Contact Us | Site Map | webmaster@cvt.com
© 1999-2008, CV Therapeutics, Inc. All rights reserved.
 
spacer
Please Note: The websites of CV Therapeutics, Inc. are not intended to provide medical advice,
nor is any information here a substitute for professional healthcare. Consult your doctor or other
healthcare provider for information about your diagnosis, treatment, or condition.